LinkedIn Thought Leadership for Life-Sciences Teams

A chief scientific officer at a mid-stage biotech agrees, after months of gentle pressure from her comms team, to post on LinkedIn. The first attempt is a paragraph of press-release language about a “transformative milestone,” approved by three people, that reads like it was written by a committee because it was. It gets eleven likes, mostly from her own employees. She concludes, reasonably, that LinkedIn is a waste of a serious scientist’s time, and goes quiet again.

She is half right. Corporate broadcast on LinkedIn is a waste of time. But the platform is also where a meaningful share of your field, investors, potential hires, collaborators, and partners, actually forms its impression of who is worth paying attention to. The problem is not the channel. It is treating a conversational medium like a press-release distribution list.

The audience is smaller and sharper than you think

Life-sciences LinkedIn is not a mass audience. It is a few thousand people who matter enormously: the VC partner who will lead your next round, the senior scientist you want to recruit, the business-development lead at a pharma company scouting for assets, the journalist who covers your space. These people can smell manufactured enthusiasm instantly, and they discount it just as fast. What earns their attention is the opposite of press-release language: a genuine point of view, a specific observation from inside the work, an honest take on a hard problem.

This changes what “good” looks like. A post that admits a technical challenge and how the team is thinking about it will outperform a triumphant milestone announcement, because the first is a mind at work and the second is a marketing artifact.

Thought leadership means having an actual thought

The phrase is overused to the point of meaninglessness, but the underlying idea is real. Your scientists and executives know things most people in the field do not. They have a view on where a modality is heading, a hard-won lesson about a class of targets, a contrarian read on a hyped approach. That knowledge, expressed plainly and specifically, is thought leadership. A generic post about “the future of the industry” is not, because anyone could have written it.

The barrier is rarely that your experts have nothing to say. It is that they are busy, cautious about saying something wrong in public, and unwilling to sound like marketing. Solving that is partly editorial and partly a matter of process: capturing what they actually think, in conversation, and shaping it into something publishable without sanding off the specificity that made it worth reading. Careful content and copywriting support here is not ghostwriting opinions; it is helping a busy expert get a real one out of their head and onto the page in their own register.

Cadence beats intensity

One brilliant post a quarter builds nothing. A steady rhythm of thoughtful posts, even short ones, compounds, because the audience starts to recognize the voice and anticipate it. This does not require daily output. It requires reliability. A CSO who posts one genuinely useful observation every couple of weeks will, over a year, become a person the field pays attention to. A CSO who posts five times in a launch week and then vanishes will not.

The practical answer is a light editorial system: a running list of ideas captured whenever an expert says something interesting in a meeting, a simple review path that respects regulatory and disclosure limits without grinding every post into paste, and a realistic schedule that survives a busy quarter.

Personal voice, within real constraints

Life sciences has genuine limits on what can be said in public. Material information, unpublished data, forward-looking claims, and regulated product language all constrain what an executive can post. These are real and non-negotiable. But they are narrower than most comms teams treat them. The space between “reveal nothing” and “reveal something you should not” is wide, and it is where all the good content lives: perspective, judgment, questions, reactions to others’ work, reflections on the craft of building a company. Working within the constraints while still sounding like a human being is a learnable skill, not an impossibility.

The profile and the destination matter too

Attention earned on LinkedIn goes somewhere. When the VC partner who liked your CSO’s post clicks through to learn more, the company website is what they find, and a sharp post landing on a stale site squanders the momentum. The channel and the destination have to be built to the same standard, which is why thoughtful web design and development and a considered social presence are two ends of the same effort, not separate projects.

Where North Sea Strategic fits

We help companies across the pharma and life sciences sector turn genuine expertise into a presence the right people notice, on LinkedIn and on the site that attention flows to. We are comfortable working inside disclosure and regulatory constraints, and we care about preserving the specific, credible voice that makes an expert worth following rather than flattening it into corporate broadcast. The goal is not virality. It is a handful of the right people concluding, over time, that your team is worth knowing.

If your leaders have more to say than your channels are currently capturing, start a project with us.